Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro can be associated with hair loss, though it is not a direct pharmacological side effect of tirzepatide itself. Hair shedding reported on Mounjaro is almost always telogen effluvium — a temporary, stress-related disruption to the hair growth cycle triggered by rapid weight loss and reduced calorie intake, not by the medicine acting on your hair follicles. It typically appears two to four months after treatment begins and, for most people, resolves on its own as the body adjusts. Mounjaro is a prescription-only medicine; whether it is appropriate for you is assessed by a clinical prescriber, not decided over the counter.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a genuinely unsettling moment. The treatment is working; the scales are moving in the right direction. Then you notice the brush looks fuller, or there's more hair collecting in the plughole after a shower. For many people on Mounjaro, this happens somewhere between the eight-week and sixteen-week mark, and the immediate worry is that the medicine is damaging their hair.
The reality is more reassuring. The NHS describes telogen effluvium as a common, temporary form of hair loss in which a larger-than-usual proportion of hairs shift into the resting (telogen) phase of the growth cycle simultaneously, then shed together a few months later. The trigger is almost always a significant physiological stress, illness, surgery, hormonal change, nutritional shift, or rapid weight loss. When you lose weight quickly, as many people do on tirzepatide, your body registers it as a physical stressor even when the outcome is beneficial. The follicles respond by pausing growth, and the shed arrives weeks after the trigger, which is why the timing can catch people off guard.
Tirzepatide itself is not known to damage hair follicles directly. The pattern seen clinically is consistent with weight-loss-related effluvium rather than drug toxicity. The NHS medicines page for tirzepatide lists hair loss among reported side effects, reflecting the real-world picture, but the mechanism sits with caloric restriction and metabolic change, not with the molecule.
Mounjaro works partly by reducing appetite significantly. That is exactly the point. But a sharply reduced appetite also means some people eat far less protein and fewer micronutrients than their body needs, particularly in the early months before eating patterns settle. Protein is the raw material for keratin, the structural protein that makes up each hair strand. When intake drops, the body prioritises protein for essential functions and deprioritises hair growth. Iron, zinc and B-complex vitamins follow a similar logic.
Diets that produce gradual weight loss over a long period rarely trigger the same response because the stress is spread out. A 10–15% reduction in body weight over several months concentrates physiological change in a shorter window, and the follicular response is correspondingly more noticeable. This is the same reason hair shedding is common after bariatric surgery, after a serious illness, or after any rapid dietary change, the mechanism is well established and not unique to GLP-1 medicines.
If you want to understand more about the broader experience of hair falling out on Mounjaro, including what patients typically report and how long it lasts, there is more detail on that page. The short version: for most people, shedding peaks and then stabilises. The follicles are not destroyed; they recover.
The most consistent practical advice is nutritional. Aim to keep protein intake at or above 1.2–1.6 g per kilogram of body weight per day while on Mounjaro, a target your prescriber or a dietitian can help you personalise. Because appetite is reduced, hitting that figure can take conscious effort: prioritising protein at every meal before filling up on lower-density foods is a practical approach. Staying well hydrated matters too, as does checking for deficiencies: iron, ferritin, zinc, vitamin D and B12 are all worth reviewing with your GP if shedding is noticeable, because a pre-existing deficiency can be amplified by dietary change.
There is no strong evidence that topical treatments or specialist shampoos reverse telogen effluvium. Time and nutritional recovery are the primary drivers of regrowth. Stopping Mounjaro is not usually indicated for this reason alone, particularly when weight loss is progressing well, but that is a conversation to have with your prescriber, who can weigh the full picture. Understanding the realistic cost context of Mounjaro treatment is also useful when planning for a course of several months, since consistent treatment tends to produce better outcomes than stopping and restarting.
One thing our prescribers hear fairly often: patients assume the hair loss means the medicine is harming them and stop treatment prematurely. The reassuring biology here is that the follicles in telogen effluvium are dormant, not dead. Regrowth typically begins within three to six months of the peak shed, often while you are still on the medicine. The NHS guidance on hair loss covers telogen effluvium and its expected course in more detail.
Most hair shedding on Mounjaro does not need urgent investigation. However, a few patterns are worth flagging promptly. If you are wondering whether Mounjaro makes you lose hair and whether it is a direct effect of the medicine or something else, that question is explored in more depth on its own page. If shedding has not slowed after six months on a stable dose, it is worth checking thyroid function, hypothyroidism can both cause hair loss and occasionally be triggered by significant metabolic change. Heavy shedding alongside fatigue, brittle nails, or cold intolerance suggests anaemia or thyroid disruption rather than effluvium alone, and if you are also asking whether you can lose your hair on Mounjaro in a more permanent sense, that page sets out what the evidence shows about long-term follicle health.
You can raise any of these concerns through your nume prescriber at any point via our aftercare team, or with your GP. Some patients also ask specifically whether Mounjaro thins your hair in a way that changes its texture or density over time, rather than simply causing a temporary shed, and that page looks at what the evidence actually shows. If you have specific questions about a dose stage, the 12.5mg step page covers what higher doses typically mean for appetite, side effects and monitoring.
Mounjaro is a prescription medicine that requires a clinical assessment before it is started or continued. If you are ready to speak to a prescriber, start your free consultation and a GPhC-registered clinician will review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.